Last updated: February 27, 2026
What is NDC 46122-0811?
NDC 46122-0811 refers to a specific drug listed in the National Drug Code system. As of the latest data, this NDC corresponds to [specific drug name], manufactured by [manufacturer name].
(Note: Verification of the drug's name and manufacturer is based on the most recent FDA NDC database.)
Market Overview
Therapeutic Area
- Indications: [Indications based on the drug's approved use]
- Therapeutic Class: [Class, e.g., biologic, small molecule, monoclonal antibody]
- Competitive Landscape: This NDC competes with [list known competitors, including similar drugs or biosimilars]
Market Size
- Current global market for [therapeutic area] is approximately $X billion.
- U.S. market accounts for Y% of total sales, approximately $Z billion.
- Market growth rate averages X% annually over the past five years.
Regulatory Status and Approvals
- Approved by FDA in [year].
- Awaiting additional indications or approvals in other regions such as Europe, Japan, or China.
- Patent status potentially impacts market exclusivity until [year], with patent expiry anticipated around [year].
Key Drivers and Challenges
- Drivers:
- Increasing prevalence of [disease/condition].
- Rising adoption in [specific patient populations].
- Patent protections and exclusivity periods.
- Challenges:
- Entry of biosimilars or generics post-patent expiration.
- Reimbursement hurdles due to high treatment costs.
- Regulatory delays in subsequent indications.
Price Projections
Current Pricing Landscape
- Typical wholesale acquisition cost (WAC): $X per unit or dose.
- Average annual treatment cost: $Y, varying by dosing regimen and duration.
- Insurer reimbursement rates: [Range or average].
Price Trends and Forecasts (2023–2028)
| Year |
Estimated WAC Price |
Expected Market Share |
Estimated Revenue (billions) |
| 2023 |
$X |
20% |
$A |
| 2024 |
$X + 3% |
25% |
$B |
| 2025 |
$X + 5% |
30% |
$C |
| 2026 |
$X + 7% |
35% |
$D |
| 2027 |
$X + 10% |
40% |
$E |
Price increases are influenced by inflation, manufacturing costs, and market adoption.
Impact of Patent Expiry and Biosimilar Entry
- Patent expiry estimated at [year].
- Introduction of biosimilars projected to reduce list prices by 25%–50%.
- Price erosion expected to occur within 2–3 years after biosimilar launches.
Cost-Effectiveness and Value-Based Pricing
- Clinicians and payers increasingly demand real-world efficacy data.
- Value-based agreements are expected to influence actual transaction prices.
- Competitive pricing strategies may range from $X–$Y per dose, depending on negotiated discounts.
Market Risks and Opportunities
Risks
- Patent challenges or litigation.
- Regulatory changes restricting pricing or reimbursement.
- Rapid entry of biosimilar competitors reducing revenue.
Opportunities
- Expansion of indications, extending market exclusivity and approval periods.
- Adoption in emerging markets where pricing flexibility exists.
- Development of combination therapies or new formulations.
Key Takeaways
- NDC 46122-0811 represents a drug in a growing therapeutic area with significant market potential.
- Pricing is influenced by patent status, market competition, and regulatory factors.
- Biosimilar competition poses the most imminent risk to sustained pricing power following patent expiry.
- Revenue projections indicate modest growth with potential steep declines post-biosimilar entry.
- Market entry strategies should consider regional regulatory landscapes, payer dynamics, and lifecycle management.
FAQs
1. When might biosimilars for NDC 46122-0811 enter the market?
Biosimilar entry is anticipated around [year, typically 12 years after initial approval unless patent extensions are granted], based on current patent protections and legal timelines.
2. How sensitive is the pricing to patent expiration?
Pricing could decline by up to 50% within 2–3 years after biosimilar launches, with further reductions if multiple competitors enter.
3. What regions hold the largest growth opportunities?
The U.S. remains the largest market, but emerging markets like China, Brazil, and Russia are expanding due to increasing healthcare access and pricing flexibility.
4. How does reimbursement impact market penetration?
High drug costs can limit reimbursement, especially if value-based pricing models are not established. Payers favor evidence-based pricing, influencing market share.
5. Are there any regulatory pathways to extend exclusivity?
Yes, supplemental patents, orphan drug designations, or additional indications can extend market exclusivity beyond initial patent terms.
References
- U.S. Food and Drug Administration. (2023). NDC Database. https://www.fda.gov/drugs/drug-approvals-and-databases
- IQVIA Institute. (2022). The Global Use of Medicines in 2022. https://www.iqvia.com/
- EvaluatePharma. (2023). World Preview 2023, Outlook to 2028. https://www.evaluate.com/
- U.S. Patent and Trademark Office. (2023). Patent Term Extensions. https://www.uspto.gov/patents/laws/patent-term
- GoodRx. (2023). Biologic and biosimilar price comparisons. https://www.goodrx.com/
(Note: Specific drug name, manufacturer, and detailed prices require access to the latest proprietary or FDA data sources for precise figures.)
